Elicio Therapeutics, Inc.
ELTX
$8.05
$0.091.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.90% | -11.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.33% | 30.28% | |||
| Operating Income | 20.33% | -30.28% | |||
| Income Before Tax | 19.96% | 25.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.96% | 25.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.96% | 25.66% | |||
| EBIT | 20.33% | -30.28% | |||
| EBITDA | 20.22% | -30.39% | |||
| EPS Basic | 15.64% | 26.03% | |||
| Normalized Basic EPS | 15.63% | 26.03% | |||
| EPS Diluted | 15.64% | 26.03% | |||
| Normalized Diluted EPS | 15.63% | 26.03% | |||
| Average Basic Shares Outstanding | -5.13% | 0.50% | |||
| Average Diluted Shares Outstanding | -5.13% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||